STAAR Surgical Company logo STAA - STAAR Surgical Company

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 4
HOLD 10
SELL 2
STRONG
SELL 0
| PRICE TARGET: $31.50 DETAILS
HIGH: $40.00
LOW: $27.00
MEDIAN: $31.50
CONSENSUS: $31.50
UPSIDE: 36.30%

Stock News

STAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer

STAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chief Executive Officer. "Evolving STAAR from a single-product focus into a multi-product platform is cent.

Sep 02, 2026 12:01 PM • businesswire.com
American Capital Management Inc. Makes New $24.29 Million Investment in STAAR Surgical Company $STAA

American Capital Management Inc. Makes New $24.29 Million Investment in STAAR Surgical Company $STAA

American Capital Management Inc. purchased a new stake in STAAR Surgical Company (NASDAQ: STAA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 846,659 shares of the medical instruments supplier's stock, valued at approximately $24,291,000. American Capital Management Inc.

Aug 26, 2026 11:39 PM • defenseworld.net
STAAR Surgical Reports Second Quarter 2026 Results

STAAR Surgical Reports Second Quarter 2026 Results

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended July 3, 2026. Second Quarter 2026 Financial Overview Net sales of $93.5 million, up 111% Y/Y Net sales excluding China of $41.2 million, up 6.0% Y/Y China sales of $52.3 million up over 100%, 10% sequentially APAC sales up 189% Y/Y, ex-China sales up.

Aug 12, 2026 12:01 PM • businesswire.com
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that following an extensive global search, its Board of Directors (the "Board") has appointed Warren Foust as President and Chief Executive Officer and a new member of the Board of Directors, effective August 4, 2026. Mr. Foust joined STAAR in April 2023 and h.

Aug 04, 2026 12:05 PM • businesswire.com
STAAR Surgical's Punishment For Opacity Is Just

STAAR Surgical's Punishment For Opacity Is Just

STAAR Surgical Company shares fell sharply after preliminary Q2 2026 sales met expectations but lacked forward guidance, raising investor concerns. STAA demonstrated robust revenue growth, especially in China and the Americas, with improved margins and cost discipline, but EMEA sales lagged due to geopolitical issues. Despite recent profitability and a strong cash position, uncertainty remains over the sustainability of these improvements and the absence of detailed guidance.

Jul 17, 2026 01:31 PM • seekingalpha.com
STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026

STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second quarter ended July 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement, which it expects to issue on August 12, 2026.Net sales for the second quarter of 2026 are expected to be in excess of.

Jul 16, 2026 12:01 PM • businesswire.com
STAAR Surgical Announces Participation in Upcoming Investor Conferences

STAAR Surgical Announces Participation in Upcoming Investor Conferences

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026 Format: Meetings and Webcast Fireside Chat Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm. Webcas.

May 21, 2026 12:01 PM • businesswire.com
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround

STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround

STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China's market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval.

May 16, 2026 06:10 AM • seekingalpha.com

Price Targets